Strides Pharma Science posts consolidated net loss of Rs 149 crore in Q2

Published On 2023-10-30 04:30 GMT   |   Update On 2023-10-30 10:00 GMT
Advertisement

New Delhi: Strides Pharma Science has reported a consolidated net loss of Rs 149 crore for the second quarter ended September 30, 2023.

The drug firm had reported a net profit of Rs 19 crore for the year-ago period.

Total income, however, rose to Rs 1,035 crore in the second quarter as compared with Rs 920 crore in the year-ago period, Strides Pharma said in a regulatory filing.

"The significant loss for the current quarter and half year ended September 30 has been on account of continuing operating losses, finance costs and others," the drug firm said.

Advertisement

Read also: Strides to sell manufacturing facility in Singapore for Rs 125 crore

Strides is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.

Read also: Strides Pharma bags USFDA nod for Efavirenz, Emtricitabine, Tenofovir Disproxil Fumurate tablets for HIV

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News